Vedomosti: Russia will conduct the third phase of trials of the South Korean drug against COVID-19
Photo: Sebastian Gollnow / dpa / Global Look Press
The drug from the coronavirus of the South Korean company Chong Kun Dang Pharmaceutical Corp will be investigated in Russia during the third phase of international clinical trials. This is reported by “Vedomosti” with reference to the state register of permits of the Ministry of Health to conduct clinical trials.
Nafamostat mesylate, which is used in acute pancreatitis, as well as as an anticoagulant during extrarenal blood purification, will be used to treat patients hospitalized with coronavirus.
The second phase of trials of the South Korean drug involved 104 patients with coronavirus pneumonia. The researchers compared standard therapy in 51 people with the same treatment but in combination with a nafamostat in 53 people. As a result, 36 participants with a severe course of the disease when using nafamostat reduced the time to clinical improvement – 11 days versus 14 days without it.
In case of successful results of the third phase of trials, nafabellan will be used in the treatment of patients with severe cases of the disease. Companies such as R-Pharm and Pharmstandard can become partners of the new foreign drug in Russia, Vedomosti writes.
On December 22, the Russian Ministry of Health registered a new drug for coronavirus called Mir 19. The drug selectively inhibits the activity of vital viral RNA sequences, but does not affect the human genome. To deliver the substance to the upper and lower respiratory tract, it contains a cationic dendrimeric peptide.
